These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 16876746)

  • 1. Validation of a model for predicting drug-induced torsades de pointes: the risky business of assessing arrhythmogenic potential.
    Yamada KA; Nerbonne JM
    Heart Rhythm; 2006 Aug; 3(8):957-8. PubMed ID: 16876746
    [No Abstract]   [Full Text] [Related]  

  • 2. Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias.
    Liu T; Brown BS; Wu Y; Antzelevitch C; Kowey PR; Yan GX
    Heart Rhythm; 2006 Aug; 3(8):948-56. PubMed ID: 16876745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative contributions of TRIaD and QT to proarrhythmia.
    Hondeghem LM
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):655-7. PubMed ID: 17488264
    [No Abstract]   [Full Text] [Related]  

  • 4. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
    Milberg P; Hilker E; Ramtin S; Cakir Y; Stypmann J; Engelen MA; Mönnig G; Osada N; Breithardt G; Haverkamp W; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):647-54. PubMed ID: 17388913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation.
    Di Diego JM; Belardinelli L; Antzelevitch C
    Circulation; 2003 Aug; 108(8):1027-33. PubMed ID: 12912819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of sensitivity of surrogate markers of drug-induced torsades de pointes in canine hearts.
    Chiba K; Sugiyama A; Takasuna K; Hashimoto K
    Eur J Pharmacol; 2004 Oct; 502(1-2):117-22. PubMed ID: 15464097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs.
    Thomsen MB; Verduyn SC; Stengl M; Beekman JD; de Pater G; van Opstal J; Volders PG; Vos MA
    Circulation; 2004 Oct; 110(16):2453-9. PubMed ID: 15477402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Torsade de pointes: a new way to kill drugs].
    Tamargo Menéndez LJ
    An R Acad Nac Med (Madr); 1998; 115(1):23-42; discussion 42-6. PubMed ID: 9741134
    [No Abstract]   [Full Text] [Related]  

  • 9. Self-Terminating Ventricular Fibrillation in Vandetanib-Induced Torsades de Pointes.
    Loffi M; Toffetti L; Gianni C; Lombardi F
    J Cardiovasc Electrophysiol; 2015 Jul; 26(7):811-3. PubMed ID: 25648339
    [No Abstract]   [Full Text] [Related]  

  • 10. [Torsades de pointes ventricular tachycardia induced by intravenous amiodarone].
    Makai A; Rudas L; Liszkai G; Fazekas T
    Orv Hetil; 2003 Feb; 144(5):241-7. PubMed ID: 12647553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of torsades de pointes in rabbit ventricles perfused with sedating and nonsedating histamine H1-receptor antagonists.
    Gilbert JD; Cahill SA; McCartney DG; Lukas A; Gross GJ
    Can J Physiol Pharmacol; 2000 May; 78(5):407-14. PubMed ID: 10841436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early afterdepolarization in a patient with complete atrioventricular block and torsades de pointes.
    Kurita T; Ohe T; Shimizu W; Hotta D; Shimomura K
    Pacing Clin Electrophysiol; 1993 Jan; 16(1 Pt 1):33-8. PubMed ID: 7681173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrocardiographic Abnormalities, Malignant Ventricular Arrhythmias, and Cardiomyopathy Associated With Loperamide Abuse.
    Vaughn P; Solik MM; Bagga S; Padanilam BJ
    J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1230-1233. PubMed ID: 27461785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates.
    Guo L; Dong Z; Guthrie H
    J Pharmacol Toxicol Methods; 2009; 60(2):130-51. PubMed ID: 19616638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
    Said TH; Wilson LD; Jeyaraj D; Fossa AA; Rosenbaum DS
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):165-71. PubMed ID: 22561361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revised definition of M cell and torsade de pointes in long QT syndrome.
    Takahashi N
    J Cardiovasc Electrophysiol; 2005 Sep; 16(9):988-90. PubMed ID: 16174021
    [No Abstract]   [Full Text] [Related]  

  • 17. [Experimental models of torsades de pointes].
    Davy JM; Weissenburger J; Chezalviel F; Ertzbischoff O
    Arch Mal Coeur Vaiss; 1992 Dec; 85 Spec No 4():15-21. PubMed ID: 1307190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Torsades de pointes tachycardia induced by common cold compound medication containing chlorpheniramine.
    Nia AM; Fuhr U; Gassanov N; Erdmann E; Er F
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1173-5. PubMed ID: 20676621
    [No Abstract]   [Full Text] [Related]  

  • 19. Early afterdepolarizations, U waves, and torsades de pointes.
    Wu J; Wu J; Zipes DP
    Circulation; 2002 Feb; 105(6):675-6. PubMed ID: 11839619
    [No Abstract]   [Full Text] [Related]  

  • 20. An antibiotic recipe for an arrhythmic disaster.
    McCutcheon K; Manga P
    Cardiovasc J Afr; 2015; 26(3):143-5. PubMed ID: 26592910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.